Business Context and Reporting Period
This Form 8-K was filed by Acrivon Therapeutics, Inc. on March 25, 2025. The report details preliminary financial liquidity as of December 31, 2024, and provides significant updates on clinical development programs for its lead asset ACR-368 and second asset ACR-2316. The company is an emerging growth company focused on oncology therapeutics.
Key Financial Metrics
- Cash and Investments: Preliminary cash, cash equivalents, and short-term investments balance of approximately $184.6 million as of December 31, 2024.
- Liquidity Runway: Management believes current resources are sufficient to fund operations into 2027.
- Revenue and Profit: The filing does not provide specific revenue, profit, or cash flow figures for the period.
- Debt: No debt figures are disclosed in this report.
Material Changes and Clinical Updates
ACR-368 (Endometrial Cancer)
- BM+ Patients (Monotherapy): In 20 Oncosignature-positive (BM+) patients with aggressive, refractory tumors, the confirmed Overall Response Rate (ORR) was 35% and Disease Control Rate (DCR) was 80%. Notably, in 12 patients refractory to prior therapy, the ORR was 33%.
- BM- Patients (Combination): In 38 Oncosignature-negative (BM-) patients treated with ACR-368 plus ultra-low dose gemcitabine (LDG), the confirmed ORR was approximately 13%.
- Strategic Pivot: The company has officially deprioritized ovarian and bladder cancer indications due to competitive pressures and lower-than-expected BM+ rates. All clinical resources are now reallocated to endometrial cancer and ACR-2316.
ACR-2316 (Phase 1 Solid Tumors)
- Progress: The Phase 1 trial is ahead of schedule, having completed Dose Level 3 without safety concerns or dose-limiting toxicities.
- Activity: Initial clinical activity was observed in a patient at Dose Level 3, showing significant reduction in metastatic lesions.
- Target Engagement: Drug target engagement was detected in peripheral blood mononuclear cells at Dose Level 1.
Guidance, Outlook, and Risks
- Outlook: Endometrial cancer remains the prioritized indication for ACR-368, with an estimated 27,000 U.S. patients annually in the second-line setting. The company expects to explore ACR-368 + LDG in BM+ patients in future studies.
- Financial Warning: The $184.6 million cash balance is preliminary and subject to change as final consolidated financial statements for 2024 are not yet finalized.
- Risks: The filing notes that the preliminary financial data should not be relied upon unduly. Clinical success remains contingent on ongoing trial results and regulatory pathways.
Investor Verification Checklist
- Verify the final audited cash balance for December 31, 2024, once the annual report is filed, as the current $184.6 million figure is preliminary.
- Monitor upcoming data presentations regarding the ACR-368 + LDG combination therapy in BM- patients to confirm sensitization effects.
- Track enrollment and safety data for the ACR-2316 Phase 1 trial as it progresses beyond Dose Level 3.
- Review the full R&D Event Presentation (Exhibit 99.1) for detailed clinical data tables and management commentary not fully summarized in the text.